• Explore /
  • Poster
  • / EXCEED-ET: A single-arm multicenter study to assess the efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft (P1101) in North American adults with essential thrombocythemia.

EXCEED-ET: A single-arm multicenter study to assess the efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft (P1101) in North American adults with essential thrombocythemia.

Abstract Poster

Authors

null

Lucia Masarova

MD Anderson Cancer Center, Houston, TX

Lucia Masarova , John Mascarenhas , Albert Qin , Weichung Shih , Toshiaki Sato , Raymond Urbanski , Oleh Zagrijtschuk , Craig Zimmerman

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies

Sub Track

Myeloproliferative Neoplasms (MPN) and Mast Cell Disorders

Clinical Trial Registration Number

NCT05482971

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS7088)

DOI

10.1200/JCO.2023.41.16_suppl.TPS7088

Abstract #

TPS7088

Poster Bd #

210b

Abstract Disclosures

Similar Posters

First Author: Joseph Kim

First Author: Haris Ali

First Author: Ciro Roberto Rinaldi

First Author: Kristen McCullough